Atreca Investor Relations Material

Atreca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based immunotherapeutics for the treatment of various solid tumor types. Utilizing a novel discovery platform, Atreca's leading product candidate, ATRC-101, is a monoclonal antibody designed with a unique mechanism of action, derived from an antibody identified through this platform. ATRC-101 has demonstrated reactivity in vitro with a wide range of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. In addition to ATRC-101, Atreca is advancing other product candidates, such as APN-497444, an antibody-drug conjugate (ADC) targeting a novel tumor glycan, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.